Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.

The vaccine programme builds on Janssen’s AdVac and PER.C6 technologies.

Under the agreement, worth around $135m, Emergent will offer drug substance manufacturing services using its molecule-to-market CDMO offering.

The services will support investments from J&J starting this year.

Emergent will reserve some large-scale manufacturing capacity to prepare for commercial manufacturing of the adenovirus-based Covid-19 vaccine beginning next year.

The companies are also considering a long-term commercial manufacturing agreement to help reach J&J’s goal of supplying one billion doses of a vaccine against Covid-19.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Emergent will carry out large-scale manufacturing of drug substance for the vaccine candidate at its Baltimore Bayview facility.

Emergent BioSolutions senior vice-president and CDMO business unit head Syed Husain said: “We share with our partners the same urgency to combat Covid-19 and will leverage our talents, capabilities, and capacities up to 300 million doses to advance this much-needed vaccine candidate and ensure ongoing commercial supply through our CDMO services.”

J&J said that preparations for clinical vaccine production are already underway at its facility in Leiden, the Netherlands. The company intends to begin Phase I clinical trials of the vaccine in September this year.

Furthermore, the company plans to rapidly scale-up worldwide vaccine manufacturing capabilities, including boosting of capacity in ex-US countries.

Additional global capacity should enable rapid production of a vaccine and the supply of more than one billion doses globally.

Johnson & Johnson chief scientific officer Paul Stoffels said: “We have set a high bar. Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise.”

According to J&J, this agreement marks the first of potential global deals to expedite manufacture of its Covid-19 vaccine candidate.